摘要
目的:探讨精蛋白生物合成人胰岛素(诺和灵30R)注射液对初发2型糖尿病(T2DM)患者糖脂代谢及胰岛素抵抗的影响。方法:选择2019年1月-2020年4月本院收治的初发T2DM患者160例作为研究对象,按随机数表法分为两组,各80例。对照组给予降糖药物口服,观察组诺和灵30R皮下注射。比较两组糖脂代谢水平[空腹血糖(FPG)、餐后2 h血糖(2 h PG)、三酰甘油(TG)、总胆固醇(TC)]、空腹胰岛素(FINS)及胰岛素抵抗指数(HOMA-IR)。结果:治疗结束时,两组FPG、2 h PG、TG、TC较治疗前降低,观察组低于对照组,差异有统计学意义(P<0.05);两组FINS较治疗前升高,观察组高于对照组,HOMA-IR较治疗前降低,观察组低于对照组,差异有统计学意义(P<0.05)。结论:诺和灵30R治疗初发T2DM,可显著改善患者糖脂代谢,提高胰岛素水平,降低胰岛素抵抗。
Objective:To investigate the effect of Protamine Biosynthetic Human Insulin(Novolin 30R)Injection on glucose and lipid metabolism and insulin resistance in newly diagnosed type 2 diabetes mellitus(T2DM).Method:A total of 160 patients with newly diagnosed T2DM in our hospital from January 2019 to April 2020 were selected and randomly divided into two groups,80 cases in each group.The control group was given oral hypoglycemic drugs,and the observation group was subcutaneously injected with Novolin 30R.The levels of glucose and lipid metabolism(FPG,2 h PG,TG,TC),fasting insulin(FINS)and insulin resistance index(HOMA-IR)were compared between the two groups.Result:At the end of treatment,FPG,2 h PG,TG and TC in the two groups were lower than those before treatment,and the observation group were lower than the control group,the differences were statistically significant(P<0.05);FINS in the two groups was higher than that before treatment,the observation group was higher than the control group,HOMA-IR was lower than that before treatment,the observation group was lower than the control group,the differences were statistically significant(P<0.05).Conclusion:Novolin 30R can significantly improve glucose and lipid metabolism,increase insulin level and reduce insulin resistance in patients with newly diagnosed T2DM.
作者
冯伟杰
成明建
钟天文
江小兰
FENG Weijie;CHENG Mingjian;ZHONG Tianwen;JIANG Xiaolan(Yunfu People’s Hospital,Yunfu 527300,China;不详)
出处
《中外医学研究》
2021年第14期86-88,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
初发2
型糖尿病
精蛋白生物合成人胰岛素
糖脂代谢
胰岛素抵抗
Primary type 2 diabetes mellitus
Protamine biosynthesis of human insulin
Glucose and lipid metabolism
Insulin resistance
